DFTX
Definium Therapeutics, Inc. trades as DFTX and has a market capitalization of $2.53 B, making it the #1939 largest US-listed company by market value. This page tracks Definium Therapeutics, Inc. through 445 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-19 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Major company event | 8-K | 2026-05-12 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Proxy materials | DEFA14A | 2026-04-27 |
| Proxy statement | DEF 14A | 2026-04-27 |
| Major company event | 8-K | 2026-04-22 |
The largest companies sharing Definium Therapeutics, Inc.'s SEC industry classification (medicinal chemicals & botanical products).
Definium Therapeutics, Inc. (DFTX) has a market capitalization of $2.53 B as of 2026-06-10, ranking #1939 among US-listed companies.
In its latest fiscal year Definium Therapeutics, Inc. reported a net loss of $183.79M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.